A Patent Review on SARS Coronavirus Main Protease (3CLpro ) Inhibitors.
ChemMedChem
; 17(1): e202100576, 2022 01 05.
Article
in English
| MEDLINE | ID: covidwho-1626179
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is an unprecedented global health emergency causing more than 4.2 million fatalities as of 30â
July 2021. Only three antiviral therapies have been approved or granted emergency use authorization by the FDA. The SARS-CoV-2 3CL protease (3CLpro ) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis, although no inhibitors have been approved. This patent review discusses SARS coronavirus 3CLpro inhibitors that have been filed up to 30â
July 2021, giving an overview on the types of inhibitors that have generated commercial interest, especially amongst drug companies. Insights into the common structural motifs required for active site binding is also discussed.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Patents as Topic
/
Cysteine Proteinase Inhibitors
/
Coronavirus 3C Proteases
Limits:
Humans
Language:
English
Journal:
ChemMedChem
Journal subject:
Pharmacology
/
Chemistry
Year:
2022
Document Type:
Article
Affiliation country:
Cmdc.202100576
Similar
MEDLINE
...
LILACS
LIS